{
    "eid": "2-s2.0-85074667265",
    "title": "Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study",
    "cover-date": "2019-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Endocrinology, Diabetes and Metabolism",
            "@code": "2712",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Orthopedics and Sports Medicine",
            "@code": "2732",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "BONE MINERAL DENSITY",
        "BONE TURNOVER",
        "HIV",
        "SWITCHING",
        "TENOFOVIR",
        "ZOLEDRONIC ACID"
    ],
    "authors": [
        "Andrew Carr",
        "Stephen J. Kerr",
        "Robyn Richardson",
        "Peter Ebeling",
        "Nicholas Pocock",
        "Jhon Rojas",
        "Esteban Martinez",
        "Jennifer Hoy"
    ],
    "citedby-count": 9,
    "ref-count": 13,
    "ref-list": [
        "Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review",
        "Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system",
        "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study",
        "Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks",
        "Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial",
        "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study",
        "Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial",
        "The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis",
        "Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV",
        "Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men",
        "Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial",
        "Bone turnover markers: use in osteoporosis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Sydney",
            "@id": "60025702",
            "affilname": "St. Vincent's Hospital Sydney",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025702",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60019578",
            "affilname": "Monash University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019578",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60008014",
            "affilname": "The Alfred",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008014",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Barcelona",
            "@id": "60001576",
            "affilname": "Universitat de Barcelona",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001576",
            "affiliation-country": "Spain"
        }
    ],
    "funding": [
        "Balnaves Foundation",
        "Bristol\u2010Myers Squibb",
        "Novartis",
        "Gilead Sciences and ViiV Healthcare",
        "National Health and Medical Research Council of Australia"
    ]
}